Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Macular Health LLC Stories

2014-03-28 12:26:11

Patented delivery technology provides easier solutions BIRMINGHAM, Ala., March 28, 2014 /PRNewswire/ -- Macular Health, a Birmingham-based company offering nutritional products that help slow vision loss for those suffering with age-related macular degeneration (AMD), is pleased to debut two new revolutionary products - MacuSpray(TM), a new Intra-Oral Spray, and the MacuStrip(TM) Premier, a new Oral Thin Film (OTF) - both delivery methods unlike anything seen before in the realm of...

2014-03-10 16:31:49

BIRMINGHAM, Ala., March 10, 2014 /PRNewswire/ -- Macular Health's Visual Advantage, a Birmingham-based company offering nutritional products that help slow vision loss for those suffering with age-related macular degeneration (AMD), has introduced MacuStrip Premier, its new Oral Thin Film (OTF) delivery method. Macular Health President and CEO Jeffery McAnnally will announce the new product at the 2014 Optometry's Marketplace at SECO(TM) International in Atlanta, Ga., on Friday, March...

2013-08-20 08:30:52

BIRMINGHAM, Ala., Aug. 20, 2013 /PRNewswire/ -- Macular Health's Visual Advantage today became the first product made available to the public featuring the new AREDS 2 formula for the prevention of vision loss due to age-related macular degeneration (AMD). Released on May 5, 2013 by the National Eye Institute (NEI), AREDS 2 is the second largest ophthalmic study in history which confirmed that the ingredients, lutein and zexanthin effectively replace beta carotene in the original...

2013-05-23 08:28:18

MIAMI LAKES, Fla., May 23, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce, in partnership with Macular Health, LLC, advances in the development of an AREDS2 Drop formulation to combat Age-Related Macular Degeneration ("AMD"). AMD is a medical condition which...

2013-05-13 08:28:29

BIRMINGHAM, Ala., May 13, 2013 /PRNewswire/ -- The results of the second largest ophthalmic study in history were released on May 5, 2013 by the National Eye Institute (NEI) and confirms that Macular Health, LLC, a Birmingham, Ala.,-based company producing ophthalmic nutraceuticals, has had the ideal formulated product to combat Age-Related Macular Degeneration (AMD) since 2003. Macular Health's original formulation was modeled after the results of the largest ophthalmic study ever...

2013-01-15 08:24:22

MIAMI LAKES, Fla., Jan. 15, 2013 /PRNewswire/ -- Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com), an innovative consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today that in furtherance of its planned licensing relationship with Macular Health, LLC, Fuse Science has developed a DROP formulation of Macular Health's macular degeneration...

2012-08-06 06:24:04

MIAMI LAKES, Fla., Aug. 6, 2012 /PRNewswire/ -- Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com), today announced that it has entered into a licensing letter of intent ("LOI") with Macular Health, LLC, (www.macularhealth.com), one of the leading manufacturers of macular degeneration nutritional supplements. This is the first licensing agreement for Fuse Science in the health and nutrition field and accelerates the application of its unique delivery technology into a new industry...

2009-06-23 08:43:00

BIRMINGHAM, Ala., June 23 /PRNewswire/ -- According to the World Health Organization (WHO), age-related macular degeneration (AMD) ranks third as a cause of visual impairment. It is the primary cause of visual impairment in industrial countries with a blindness prevalence of 8.7 percent. A new medical study indicates, however, that with the use of the Macular Health vitamin supplement there is a way to preserve the vision of millions of aging adults suffering from AMD. The second phase of...

2009-04-28 08:43:00

Eye disease product has the potential to preserve vision for millions BIRMINGHAM, Ala., April 28 /PRNewswire/ -- As many as 17.8 million people will suffer from age-related macular degeneration (AMD) by 2050 and 1.57 million will be blind from the disease, according to the U.S. Centers for Disease Control and Prevention. However, a new medical study by a group of retina specialists at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (UAB) indicates that with the...